Malignant Central Nervous System Neoplasm

Malignant Central Nervous System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 822
Recruiting: 449
Ph III recruiting: 27
Growth YoY: +18.1%
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.9%
Trials / 1,000 deaths: 45.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (418)

clinicaltrialsPublishedShowing 751–800 of 952 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07023640	Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors	recruiting	N/A	50	Peking Union Medical College HospitalOTHER	1	Aug 5, 2025	clinicaltrials
NCT04961515	Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma	recruiting	Phase 2	19	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER	1	Jul 31, 2025